Treatments & Clinical Trials
Stay informed about the latest breakthroughs in stem cell therapies and clinical trials that hold promise for a wide range of medical conditions. Explore how groundbreaking treatments and ongoing research are paving the way for the future of healthcare.
Heart Attack Recovery: Role of Stem Cells
Explains how stem cell therapy can regenerate heart tissue after a heart attack, improve LVEF, reduce heart failure risk, and current delivery challenges.
Umbilical Cord Blood in Rare Genetic Disorder Trials
Banked cord blood and therapies like DUOC-01 show strong trial results—faster availability, lower rejection risk, and improved outcomes for many rare genetic disorders.
How Stem Cells Help Babies with Rare Conditions
Cord blood and tissue stem cell therapies show early safety and promise for repairing lung and brain injuries in newborns with BPD, HIE, and IVH.
Advances in Stem Cell Disc Regeneration
MSC therapies for degenerative disc disease: mechanisms, clinical results and safety, and emerging exosome, biomaterial, gene-editing, and stem cell banking advances.
Not Just for Babies: Cord Blood Banking Protects Your Child Into Adulthood
Explains how cord blood banking preserves newborn stem cells for 80+ treatments today and supports future adult therapies through long-term storage.
How Imaging Predicts Stem Cell Therapy Outcomes
MRI, PET/CT, and AI enable noninvasive, real-time tracking of transplanted stem cells—revealing viability, inflammation, and early indicators of success in autoimmune therapies.
Clinical Trials on Stem Cells for Orthopedic Healing
Overview of clinical trial results for stem cell therapy in orthopedic injuries: efficacy, safety, delivery methods, sources, and regulatory challenges.
Birth Tissue Sources for Stem Cells: Overview
Clear overview of cord blood, cord tissue, placenta, and amniotic fluid stem cells — collection, storage, medical uses, and ongoing clinical research.
Cord Blood vs. Bone Marrow: Recovery and Complications
Cord blood offers faster access and lower chronic GVHD but slower engraftment and higher early infection risk than bone marrow.